SAN MATEO, Calif., April 24 /PRNewswire-FirstCall/ -- NeurogesX, Inc.
(Nasdaq: NGSX), a biopharmaceutical company focused on developing novel
pain management therapies, announced today that it is scheduled to present
on Wednesday, April 30, 2008 at the Morgan Stanley Global Healthcare
Unplugged Conference. Anthony DiTonno, President and Chief Executive
Officer, will be presenting and Stephen Ghiglieri, Chief Financial Officer,
will be available to respond to questions.
Event: 2008 Morgan Stanley Global Healthcare Unplugged Conference
Date: Wednesday, April 30, 2008
Time: 2:20 p.m. ET
Place: Ritz Carlton in Key Biscayne, Florida
An audio Web cast of the Company's presentations will be available by going to the investor relations section of NeurogesX' Web site at http://www.neurogesx.com. A replay of the presentation will be available for 15 days.
About NeurogesX, Inc.
NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy. NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies. NeurogesX' marketing authorization application to the European Medicines Agency (EMEA) was accepted for review in September 2007 and NeurogesX plans to file a new drug application with the FDA in 2008 for PHN.
Safe Harbor Statement
This press release contains forward-looking statements for purposes of
the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX
disclaims any intent or obligation to update these forward-looking
statements, and claims the protection of the Safe Harbor for
forward-looking statements contained in the Act. Examples of such
statements include, but are not limited to, statements concerning future
presentations by NeurogesX and the expected benefits of NeurogesX'
potential products, including its lead product candidate NGX-4010. Such
statements are based on management's current expectations, but actual
results may differ materially due to various risks and uncertainties,
including, but not limited to, past results of clinical trials may not be
indicative of future clinical trials results; NeurogesX' product candidate
may have unexpected adverse side effects or inadequate therapeutic
efficacy; positive results in clinical trials may not be sufficient to
obtain FDA or European regulatory approval; physician or patient reluctance
to use NGX-4010, if approved, or the inability of physicians to obtain
sufficient reimbursement for such procedures; potential alternative
therapies; maintaining adequate patent or trade secret protection without
violating the intellectual property rights of others; and other
difficulties or delays in clinical development, obtaining regulatory
approval, market acceptance and commercialization of NGX-4010 and the
advantages of NGX-4010 over other pain therapies. For further information
regarding these and other risks related to NeurogesX' business, investors
should consult NeurogesX' filings with the Securities and Exchange
NeurogesX The Ruth Group
Stephen Ghiglieri Investors / Media
(650) 358-3310 Stephanie Carrington / Jason Rando
email@example.com (646) 536-7017 / 7025
|SOURCE NeurogesX, Inc.|
Copyright©2008 PR Newswire.
All rights reserved